Abstract:Shark VNAR nanobodies targeting the S2 subunit of SARS‐CoV‐2 spike protein were identified from a naïve nurse shark VNAR phage display library by phage panning. The S2A9 VNAR showed the best neutralization activity against the original pseudotyped virus and was further characterized. S2A9 had broad neutralization activity against different variants in both pseudovirus and live virus neutralization assays. Our results indicate that S2A9 could be a promising lead molecule in developing broadly neutralizing antibodies against SARS‐CoV‐2 and emerging variants. SARS‐CoV‐2 is the etiological agent of the COVID‐19 pandemic. Antibody‐based therapeutics targeting the spike protein, specifically the S1 subunit or the receptor binding domain (RBD) of SARS‐CoV‐2, have gained attention due to their clinical efficacy in treating patients diagnosed with COVID‐19. An alternative to conventional antibody therapeutics is the use of shark new antigen variable receptor domain (VNAR) antibodies. VNARs are small (<15 kDa) and can reach deep into the pockets or grooves of the target antigen. Here, we have isolated 53 VNARs that bind to the S2 subunit by phage panning from a naïve nurse shark VNAR phage display library constructed in our laboratory. Among those binders, S2A9 showed the best neutralization activity against the original pseudotyped SARS‐CoV‐2 virus. Several binders, including S2A9, showed cross‐reactivity against S2 subunits from other β coronaviruses. Furthermore, S2A9 showed neutralization activity against all variants of concern (VOCs) from alpha to omicron (including BA1, BA2, BA4, and BA5) in both pseudovirus and live virus neutralization assays. Our findings suggest that S2A9 could be a promising lead molecule for the development of broadly neutralizing antibodies against SARS‐CoV‐2 and emerging variants. The nurse shark VNAR phage library offers a novel platform that can be used to rapidly isolate single‐domain antibodies against emerging viral pathogens.

Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity

Screening and Optimization of Shark Nanobodies Against SARS-CoV-2 Spike RBD

Bispecific Antibodies Targeting Distinct Regions of the Spike Protein Potently Neutralize SARS-CoV-2 Variants of Concern

Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine

Identification of nurse shark VNAR single‐domain antibodies targeting the spike S2 subunit of SARS‐CoV‐2

A Class of Shark‐Derived Single‐Domain Antibodies can Broadly Neutralize SARS‐Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape

Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2

Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys

Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques

Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses

Broadly neutralizing and protective nanobodies against diverse sarbecoviruses

Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein

A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification

Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses

Potently neutralizing and protective human antibodies against SARS-CoV-2

A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2